Study of Vitamin D in the Severely Mentally Ill

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01169142
Recruitment Status : Unknown
Verified July 2015 by Nigel Bark MD, Bronx Psychiatric Center.
Recruitment status was:  Active, not recruiting
First Posted : July 26, 2010
Last Update Posted : July 21, 2015
Information provided by (Responsible Party):
Nigel Bark MD, Bronx Psychiatric Center

Brief Summary:
Supplementation of Vitamin D in those with low levels will increase the level and result in some improvement in health and psychopathology measures.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorder Dietary Supplement: Vitamin D3 Not Applicable

Detailed Description:
Subjects with levels of Vitamin D between 7ng/ml and 30ng/ml will, after signing consent forms, be randomly assigned to either start immediately on Vitamin D for three months or to start after a delay of three months. Those with levels below 7gn/ml will start immediately. All will be evaluated monthly with blood tests, PANSS, movement disorder ratings and information on health and progress from the clinical chart.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Vitamin D Supplementation in Bronx Psychiatric Patients
Study Start Date : January 2010
Actual Primary Completion Date : June 2014
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Immediate Vitamin D3
Will start Vitamin D3 immediately
Dietary Supplement: Vitamin D3
Vitamin D3 50,000 units weekly
Other Name: Cholecalciferol

Active Comparator: Three month delay
Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
Dietary Supplement: Vitamin D3
50,000 units of Vitamin D3 weekly
Other Name: Cholecalciferol

Primary Outcome Measures :
  1. Psychopathology as measured by the PANSS [ Time Frame: 3 months ]
    PANSS is being done every month

Secondary Outcome Measures :
  1. movement disorder [ Time Frame: three months ]
    AIMS (for tardive dyskinesia), Simpson-Angus (for Parkinsonism) and Barnes (for Akathisia) movement disorder rating scales will be completed monthly.

  2. General Health [ Time Frame: three months ]
    Measured by staff observation and reports, Labs for example glucose mg/dL, HgbA1c %A1c, Vitamin D ng/ml, calcium mg/dL, assessed monthly

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 19-70,
  • Schizophrenia or Schizoaffective disorder
  • stabilized but not expecting to be discharged soon
  • capacity to give informed consent

Exclusion Criteria:

  • acutely psychotic
  • acutely medically ill
  • renal insufficiency
  • hypercalcemia
  • hyperparathyroidism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01169142

United States, New York
Bronx Psychiatric Center
Bronx, New York, United States, 10461
Sponsors and Collaborators
Bronx Psychiatric Center
Principal Investigator: NIgel Bark, MD Bronx Psychiatric Center

Responsible Party: Nigel Bark MD, Director of Scizhophrenia Research, Bronx Psychiatric Center Identifier: NCT01169142     History of Changes
Other Study ID Numbers: BPCIRB0804
First Posted: July 26, 2010    Key Record Dates
Last Update Posted: July 21, 2015
Last Verified: July 2015

Keywords provided by Nigel Bark MD, Bronx Psychiatric Center:
Vitamin D
Severely Mentally Ill

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents